Trial Profile
A Prospective study to Fluorocholine-18F as predictive marker for hematological toxicity to Radium-223 therapy in patients with Castrate-resistant Prostate Cancer patients and bone metastases
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2018
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 12 Oct 2018 New trial record